Last checked at 26 Mar 2021 09:20
Syncona invests USD42 million into Gyroscope to have 54% stake
Syncona invests USD42 million into Gyroscope to have 54% stake
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Syncona Share News (SYNC)
SYNC Share
Price
SYNC Share
News
SYNC Share
Chat
SYNC Share
Trades148
SYNC
Live RNS1
SYNC Share
Charts
SYNC Level 2
Console
SYNC Live
Share Price
SYNC Broker
Ratings
SYNC Directors
Deals
SYNC Financial
Diary
SYNC
Fundamentals
SYNC Short
Positions
SYNC
Media
Syncona Information
Share Price Information for Syncona (SYNC)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
122.00
Bid:
121.20
Ask:
122.00
Change:
1.60 (1.33%)
Spread:
0.80 (0.66%)
Open:
121.00
High:
122.00
Low:
120.40
Prev. Close:
120.40
Last checked at -
Syncona is an Investment Trust
To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreWatchlists are a member only feature
Login to your account
Don't have an account? Click here to register.26 Mar 2021 07:59
Syncona invests £31m in Gyroscope
(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.
Read more25 Mar 2021 12:23
Syncona portfolio firm Achilles Therapeutics prices US share offering
Syncona portfolio firm Achilles Therapeutics prices US share offering
Read more4 Mar 2021 12:46
TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
Read more2 Mar 2021 13:45
IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO
IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO
Read more12 Feb 2021 16:24
IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test
IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test
Read more11 Feb 2021 10:05
Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell
Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell
Read more11 Feb 2021 07:56
Syncona makes decent progress in December quarter
(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.
Read more10 Feb 2021 09:41
Syncona Investee Autolus Nets USD100 Million From ADS Offer
Syncona Investee Autolus Nets USD100 Million From ADS Offer
Read more10 Feb 2021 09:31
Syncona upbeat on Autolus US public offering pricing
(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).
Read more8 Feb 2021 13:09
Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback
Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback
Read more5 Feb 2021 08:20
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read more5 Feb 2021 08:01
Syncona investment Achilles upbeat on safety review of trials
(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.
Read more6 Jan 2021 09:30
Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
Read more6 Jan 2021 08:36
Syncona upbeat on developments at Autolus
(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.
Read more